Company intelligence / Profile preview

Kitazato

Fujinomiya, JPN

Ownership: Private
Employees: ~250
Development stage: Commercial

Overview

Kitazato has established itself as a global leader in the field of assisted reproductive technologies with its Cryotop® vitrification method for oocyte and embryo cryopreservation. The company’s products are widely adopted by over 3,000 clinics worldwide and have contributed to significant improvements in IVF success rates[1][6]. Clinical studies support the effectiveness of their devices such as micromanipulators for ICSI[7].

Therapeutic areas: Women's Health
Modalities: DeviceBiologic
Industry: Consumable Medical Devices

Partnerships

Dibimed – exclusive distributor for Europe, Africa, Russia, India and South America

Beyond the preview

Go deeper on Kitazato.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Kitazato.

Explore the full profile